ATM and triple-negative breast carcinoma: For instance, ATM negatively regulates PD-L1 expression in triple-negative breast cancer (TNBC) via the JNK/c-Jun/TNF-α signalling axis, suggesting that ATM inhibition could enhance the efficacy of immune checkpoint therapy in PD-L1-negative TNBC patients.